Biotech Ardelyx Beats Shareholder Suit Over Kidney Drug

By Katryna Perera · March 18, 2024, 7:23 PM EDT

Biotechnology company Ardelyx Inc. has for now beaten a shareholder class action alleging the company and its top brass made false and misleading statements about regulatory approval of Ardelyx's drug for...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Strezsak v. Ardelyx Inc. et al

Case Number

4:21-cv-05868

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

July 30, 2021